Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs


Imatinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML). The drug shows great efficacy in chronic phase, but is less effective in maintaining hematologic remissions in blast crisis patients. Our group has previously described several cell… (More)
DOI: 10.1038/sj.leu.2402775


8 Figures and Tables